Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 2/20 | 0.36 |
| ▸ | HTR6 | P50406 | 6/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661964 | 0.88 | KCNH2 (0.78) | KCNH2MAPKAPK2CDK2HTR6 | |
| SCHEMBL30661965 | 0.84 | KCNH2 (0.55) | KCNH2MAPKAPK2APPHTR6NMT1 | |
| SCHEMBL25386410 | 0.80 | KCNH2 (0.42) | KCNH2HTR6 | |
| SCHEMBL30514112 | 0.80 | KCNH2 (0.42) | KCNH2HTR6 | |
| SCHEMBL30514108 | 0.74 | KCNH2 (0.54) | KCNH2MAPKAPK2CDK2PTGS2PTGS1 | |
| SCHEMBL25386906 | 0.74 | KCNH2 (0.54) | KCNH2MAPKAPK2CDK2PTGS2PTGS1 | |
| SCHEMBL29091990 | 0.73 | KCNH2 (0.36) | KCNH2SYK | |
| SCHEMBL30661960 | 0.70 | KCNH2 (0.71) | KCNH2APPMAPK1PTGS2PTGS1 | |
| SCHEMBL14190734 | 0.69 | HRH3 (0.59) | NMT1CTSKMAPK1 | |
| SCHEMBL30661959 | 0.68 | KCNH2 (0.49) | KCNH2CDK2MAPK1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | claimed |
| EP-4242203-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (KR) | 2023-09-13 | — | — | EP | claimed |
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (UA) | 2023-12-14 | — | — | US | disclosed |
| EP-4242203-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | Pelemed Co., Ltd. (KR) | 2023-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399320-A1 | NOVEL CAPSID ASSEMBLY INHIBITOR | ZC3HAV1, COPB1, CNBP | KCNH2 3813/4885MAPKAPK2 1160/4885APP 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.